Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 17, 2026

'We Are Going To See More Pain': Standard Chartered Cuts 2026 Bitcoin Forecast From $150K To $100K

View original at finance.yahoo.com
'We Are Going To See More Pain': Standard Chartered Cuts 2026 Bitcoin Forecast From $150K To $100K Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Slim chances of a rate cut until Kevin Warsh potentially takes office in May

    80% confidence

  • Recent cryptocurrency downturn has not led to collapse of any cryptocurrency project or company

    80% confidence

  • Ethereum could fall to $1,400 before rebounding to year-end targets

    80% confidence

  • Long-term drivers for cryptocurrency remain intact despite recent downturn

    80% confidence

  • Bitcoin will fall to $50,000 or below in the short term before rebounding

    80% confidence

  • Bitcoin ETF inflows unlikely to resume until Kevin Warsh potentially takes office in May

    80% confidence

  • Further capitulation in Bitcoin ETFs is likely as investors sit on significant losses with average purchase price of $90,000

    80% confidence

  • Current macroeconomic conditions are unfavorable for cryptocurrency

    80% confidence

  • We are going to see more pain in cryptocurrency markets

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com